Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

by | Aug 19, 2014 | 1 comment


Dr. Sean Ekins is Principal Investigator of GRIN, which is now in its second year. Dr. Ekins is a clinical pharmacologist by training with over 18 years of experience in pre-clinical drug development, toxicity and computational drug discovery research in large Pharma (Lilly, Pfizer), biotech, informatics software companies (GeneGo, Collaborative Drug Discovery, Inc.) and start up drug companies (Phoenix Nest).

As Chief Science Officer of HNF, it is his responsibility to oversee the success of our TRIAD research program in which we fund translational research (pre-clinical and clinical),  projects. HNF’s goal is to expedite the research process from bench to bedside. While there has been a considerable amount of research on CMT there is urgency to provide the thousands of patients progressing rapidly, with a therapeutic that offers a benefit to them.

As we continue to translate our research and partner with various academics, industry leaders, government and not-for-profit stakeholders that are aligned with HNF’s mission, your participation is an intricate and an important part of the process. Please Join us and contribute to GRIN, our patient registry, which will help us in our quest to cure CMT.

Learn more on this topic

Related Blog Posts

Accepting Myself for Who I Am

Growing up, I always knew I was different than my friends. I couldn’t run fast, tripped often (the scars on my knees are a reminder), was lousy at any sports-related activity, and was generally weak and uncoordinated.

The Long Road to Diagnosis Renews Dedication to Advocacy

The Long Road to Diagnosis Renews Dedication to Advocacy

Growing up we called it “Steffi disorder.” My friends and family were as baffled as my expert neurologists. I had been diagnosed with typical Spiral Muscular Atrophy (SMA) as a toddler but never followed its progression; I never seemed to get weaker. My myriad of symptoms was distinctly different than anyone else’s I had ever met in a lifetime living in the neuromuscular community. I thought I might never find my true diagnosis, let alone others who share it with me.

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Sixth Annual Card Party Brunch

On January 23, 2015 dedicated H.E.L.P. (Help Elliot Live Proud) Fund supporters participated in the 6th Annual Card Party Brunch and Boutique at Broken Sound County Club, Boca Raton, Florida. Record numbers flocked into the picturesque country club for a day filled with gourmet food, raffles, cards and a silent auction! HNF Board member Iris Adler increased this event by 50 new faces this year!

Join the conversation

Leave a Comment

1 Comment

  1. J Brian C Saunders

    Could you please give me a definition of CMT type 2 axonal
    Thanking you in anticipation



Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news